Practical EU JCA readiness for rare-disease teams
This page describes what an engagement looks like – the work we deliver, how it fits alongside the partners you already have, and where it adds something they aren’t built to do.
What we do
We work with cross-functional rare disease teams to make JCA thinking visible, clearly owned and usable at the moments when decisions are actually being shaped.
RAREready™ Asset-level working sessions
For teams who want to connect JCA thinking to real decisions on live assets now
We work with your US and EU colleagues on one or two priority assets, running structured working sessions focused on real decisions not hypothetical ones.
The aim is to establish clearly:
- What decisions are being made, and what may change when they are considered through a JCA lens
- What may be worth approaching differently and where responsibility for that sits
- Where ownership of JCA thinking could be made clearer across functions
- Where it would be useful to bring JCA thinking earlier into the asset lifecycle
This is the work that makes JCA practical – moving it from something teams are aware of to something that actively informs asset decisions.
RAREready™ JCA decision aid
For teams who want a practical tool that works inside existing processes
Based on asset-level working sessions or a review of existing materials, we develop a concise decision tool that teams can use at the moments that matter: Phase 3 design, EMA planning, post-scoping, and others.
Written in plain language and designed to sit inside existing conversations rather than add to them. It makes explicit what questions are worth asking at each stage, what good looks like, and who is best placed to raise and act on each point.
This gives distributed teams including affiliates and global functions a consistent and usable reference, at the moments when it is most needed.
RAREready™ Organisational playbook
For teams building a broader, lasting internal capability around JCA
We develop a broader, asset- or organisation-specific resource that teams can draw on as programmes evolve covering how JCA thinking should inform decisions across the lifecycle, how global and EU teams can connect around it effectively, how ownership can be handled clearly at different stages, and how to approach areas such as patient input and COI in a usable, compliant way.
Designed as a living, just-in-time resource – something teams reach for when they need it, not something they work through once and set aside.
This also gives affiliates and global functions earlier, clearer visibility – reducing the need to respond to developments once positions are already forming.
An example: EU JCA Patient Playbook for a mid-size biotech
Affiliates sit at the end of the JCA chain – small teams, no specialist expertise, under pressure when timelines run. A mid-size biotech preparing its first specialty asset for EU launch wanted to be ready for that pressure well ahead of formal scope.
We worked with the Market Access Director and a cross-functional task force to design a modular playbook around behavioural principles – and helped roll it out across central and affiliate teams so it became something they reached for at the point of need, not a document they had to remember existed.
For US-based biotech preparing for Europe
The April 2026 MFN executive order has changed the financial logic of JCA. EU reimbursement prices, shaped by JCA outcomes, now feed into US pricing exposure on the same asset.
For US-based biotech, that has moved EU JCA readiness from “something to think about for European launch” to a current commercial question with US revenue implications. We work with US biotech teams to bring EU access perspectives into global development and commercial conversations early – before the decisions that JCA will read most closely have hardened.
If you are heading toward European launch from a US base and want to test whether upstream JCA thinking is connected to where it needs to be, this is the conversation to have.